Market Research Logo

Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Dominate with Tecfidera and Ocrevus, as Disease-Modifying Pipeline Therapies for Alzheimer’s Disease and SMA Show Clinical and Commercial Potential

Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Dominate with Tecfidera and Ocrevus, as Disease-Modifying Pipeline Therapies for Alzheimer’s Disease and SMA Show Clinical and Commercial Potential

Summary


Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies.

Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to progressive decline in functional neurological capacities.

It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages. Conditions within the therapy area are diverse and exhibit specific pathophysiologies and etiologies, while affecting people of all ages.

This report examines the entire neurodegenerative disease therapy area, with a particular focus on the five most prevalent neurodegenerative disorders: Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD).

AD and PD represent the most pressing challenges within the disease cluster, due to rapidly increasing prevalence driven by aging populations. Both AD and PD remain ineffectively treated despite substantial investment into R&D by pharmaceutical companies, due to high clinical trial failure rates.

MS, the autoimmune disease of the CNS, contrasts with the rest of this cluster, as it affects a different population demographic and has a lucrative pharmacological market following breakthrough success in the past decade. Recent approvals for Ocrevus and Tecfidera are expected to sustain the market in the near future.

Scope

  • Unmet need is extremely high in AD, PD, ALS and HD, but MS and spinal muscular atrophy (SMA) show continued promise in the development of effective therapies
  • What are the most important etiological risk factors and pathophysiological processes implicated in AD, PD, MS, ALS and HD?
  • What is the current treatment algorithm?
  • How effective are current therapies for these indications and how does this impact prognosis?
  • The neurodegenerative disease pipeline is large. Does the current pipeline innovation hold the potential to change the market over the forecast period?
  • Which molecule types and molecular targets are most prominent across the five key indications?
  • What is the risk of a neurodegenerative drug failing to make the market?
  • What is the risk of a drug failing at a specific phase, molecular target class and indication?
  • The neurodegenerative disease market landscape is forecast to undergo a period of substantial change following key approvals, patent expiries and acquisitions.
  • What strategies have these companies adopted to achieve market growth?
  • Which of the leading companies will have the highest market share by 2023?
  • Which pipeline products are forecast to achieve the highest revenues on the market by 2023?
  • The deals landscape is active and dominated by immunomodulator products
  • Which indications attract the highest deal values?
  • How has deal activity fluctuated over the past decade?
  • How do deal frequency and value compare between target families and molecule types?
Reasons to buy
  • Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
  • Identify leading products and key unmet needs within the market.
  • Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target. This review also provides a detailed look at clinical trials, providing an insight into the risk associated with bringing neurodegenerative disease drugs to market.
  • Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecast will provide an understanding of how epidemiology trends, new drug entries and new drug patent expirations will influence market value.
  • Identify the key pipeline products, with a particular focus on those due to be brought to the market in the near future, including sales forecasts for these products.
  • Identify the leading companies in the market, in terms of market share and growth. Company analysis determines how dependent the key companies are on revenues derived from the neurodegenerative market. In addition, analysis determines the primary factors that will drive market growth for the key companies in the market.
  • Consider the licensing and co-development deal landscape for neurodegenerative disease drugs.


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Therapy Area Introduction
      • Alzheimer's Disease
      • Parkinson's Disease
      • Multiple Sclerosis
      • Huntington's Disease
      • Amyotrophic Lateral Sclerosis
    • Symptoms
      • Table Neurodegenerative Disease Drugs Market, Symptoms of AD, PD, MS, HD and ALS, 2017
    • Diagnosis
      • Alzheimer's Disease
      • Parkinson's Disease
      • Multiple Sclerosis
      • Huntington's Disease
      • Amyotrophic Lateral Sclerosis
    • Etiology and Pathophysiology
      • Alzheimer's Disease
      • Parkinson's Disease
      • Multiple Sclerosis
      • Huntington's Disease
      • Amyotrophic Lateral Sclerosis
    • Epidemiology
      • Table Neurodegenerative Disease Drugs Market, Global, Epidemiology, 2017
      • Alzheimer's Disease
        • Table Figure 1: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Alzheimer's Disease, 2016–2023
      • Parkinson's Disease
        • Table Figure 2: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Parkinson's Disease, 2016–2023
      • Multiple Sclerosis
        • Table Figure 3: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Multiple Sclerosis, 2016–2023
      • Huntington's Disease
        • Table Figure 4: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Huntington's Disease, 2016–2023
      • Amyotrophic Lateral Sclerosis
        • Table Figure 5: Neurodegenerative Disease Drugs Market, Global, Epidemiology Patterns for Amyotrophic Lateral Sclerosis, 2016–2023
    • Prognosis and Disease Staging
      • Alzheimer's Disease
        • Table Neurodegenerative Disease Drugs Market, Global, Alzheimer's Disease Neurological Tests and Disease Staging, 2017
      • Parkinson's Disease
        • Table Neurodegenerative Disease Drugs Market, Global, Parkinson's Disease UPRDS Scale, 2017
        • Table Neurodegenerative Disease Drugs Market, Global, Parkinson's Disease Revised Hoehn and Yahr Scale, 2017
      • Multiple Sclerosis
        • Table Figure 6: Neurodegenerative Disease Drugs Market, Global, Multiple Sclerosis Disease Profiling, 2017
      • Huntington's Disease
        • Table Neurodegenerative Disease Drugs Market, Global, Huntington's Disease Unified Huntington's Disease Rating Scale, 2017
        • Table Neurodegenerative Disease Drugs Market, Global, Huntington's Disease Shoulson and Fahn Staging Scale, 2017
      • Amyotrophic Lateral Sclerosis
        • Table Neurodegenerative Disease Drugs Market, Global, Amyotrophic Lateral Sclerosis King's Method, 2017
    • Treatment
      • Alzheimer's Disease
      • Parkinson's Disease
        • Table Neurodegenerative Disease Drugs Market, Global, Treatment Options Available for Parkinson's Disease, 2017
      • Multiple Sclerosis
      • Huntington's Disease
      • Amyotrophic Lateral Sclerosis
  • Key Marketed Products
    • Overview
      • Table Figure 7: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Key Players, 2006–2023
    • Current and Future Trends in the MS Market
      • Table Figure 8: Neurodegenerative Disease Drugs Market, Global, Market Share of Copaxone, Tecfidera, Gilenya, Avonex, Tysabri and Ocrevus Within MS, 2006–2023
    • Copaxone (glatiramer acetate) –Teva
      • Table Neurodegenerative Disease Drugs Market, Global, Approved Indications for Copaxone, 2018
      • Table Figure 9: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Copaxone ($bn), 2006–2023
    • Tecfidera (dimethyl fumarate) –Biogen
      • Table Neurodegenerative Disease Drugs Market, Global, Approved Indications for Tecfidera, 2018
      • Table Figure 10: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Tecfidera, 2013–2023
    • Gilenya (fingolimod) –Novartis
      • Table Neurodegenerative Disease Drugs Market, Global, Approved Indications for Gilenya, 2018
      • Table Figure 11: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Gilenya, 2011–2023
    • Avonex (Interferon beta-1a) –Biogen
      • Table Neurodegenerative Disease Drugs Market, Global, Approved Indications for Avonex, 2018
      • Table Figure 12: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Avonex, 2006–2023
    • Tysabri (natalizumab) –Biogen
      • Table Neurodegenerative Disease Drugs Market, Global, Approved Indications for Tysabri, 2018
      • Table Figure 13: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Tysabri, 2006–2023
    • Ocrevus (ocrelizumab) –F. Hoffmann-La Roche Ltd.
      • Table Neurodegenerative Disease Drugs Market, Global, Approved Indications for Ocrevus, 2018
      • Table Figure 14: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Ocrevus, 2017–2023
    • Namenda/Ebixa/Axura/Abixa Memary (memantine hydrochloride) –Merz/Lundbeck/Forest/Daiichi/ Sankyo
      • Table Neurodegenerative Disease Drugs Market, Global, Approved Indications for Namenda/Ebixa/Axura/Abixa/Memary, 2018
      • Table Figure 15: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Namenda/ Ebixa/ Axura/ Abixa/ Memary, 2006–2023
    • Aricept (donepezil) –Eisai/Pfizer
      • Table Neurodegenerative Disease Drugs Market, Global, Approved Indications for Aricept, 2018
      • Table Figure 16: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Aricept, 2006–2023
    • Azilect (rasagiline mesylate) –Teva
      • Table Neurodegenerative Disease Drugs Market, Global, Approved Indications for Azilect, 2018
      • Table Figure 17: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Azilect, 2006–2023
    • Neupro (rotigotine) –UCB
      • Table Neurodegenerative Disease Drugs Market, Global, Approved Indications for Neupro, 2018
      • Table Figure 18: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Neupro, 2006–2023
    • Radicut (edaravone) –Mitsubishi Tanabe Pharma Corp
      • Table Neurodegenerative Disease Drugs Market, Global, Approved Indications for Radicut 2018
      • Table Figure 19: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Radicut, 2006–2023
    • Xenazine (tetrabenazine) –Valeant Pharmaceuticals International Inc.
      • Table Neurodegenerative Disease Drugs Market, Global, Approved Indications for Xenazine, 2018
      • Table Figure 20: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Xenazine, 2006–2023
    • Spinraza (nusinersen) –Biogen
      • Table Neurodegenerative Disease Drugs Market, Global, Approved Indications for Spinraza, 2018
      • Table Figure 21: Neurodegenerative Disease Drugs Market, Global, Annual Revenue for Spinraza ($bn), 2016–2023
  • Pipeline Landscape Assessment
    • Overview
      • Table Figure 22: Neurodegenerative Disease Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
    • Pipeline Development Landscape
      • Neurodegenerative Disease Overall
        • Table Figure 23: Neurodegenerative Disease Drugs Market, Global, Pipeline by Stage of Development, Molecule Type and Program Type, 2018
      • Key Neurodegenerative Disease Indications
        • Table Figure 24: Neurodegenerative Disease Drugs Market, Global, Pipeline by Key Indications and Stage of Development, 2018
        • Table Figure 25: Neurodegenerative Disease Drugs Market, Global, Pipeline by Key Indications and Molecule Type, 2018
    • Molecular Targets in the Pipeline
      • Neurodegenerative Disease Overall
        • Table Figure 26: Neurodegenerative Disease Drugs Market, Global, Pipeline by Stage of Development and Molecular Target, 2018
        • Table Figure 27: Neurodegenerative Disease Drugs Market, Global, Pipeline by Molecular Target, 2018
      • Key Neurodegenerative Disease Indications
        • Table Figure 28: Neurodegenerative Disease Drugs Market, Global, Pipeline by Key Indications and Molecular Target, 2018
    • Clinical Trials
      • Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 29: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2018
        • Table Figure 30: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2018
        • Table Figure 31: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2018
        • Table Figure 32: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2018
      • Clinical Trial Duration by Stage of Development, Indication, Molecular Type and Molecular Target
        • Table Figure 33: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2018
        • Table Figure 34: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2018
        • Table Figure 35: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2018
        • Table Figure 36: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Duration by Stage ofDevelopment and Molecular Target (months), 2006–2018
      • Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
        • Table Figure 37: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Size by Stage of Development, 2006–2018
        • Table Figure 38: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication, 2006–2017
        • Table Figure 39: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type, 2006–2018
        • Table Figure 40: Neurodegenerative Disease Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target, 2006–2018
      • Aggregate Clinical Program Size by Stage of Development, Indication, Molecular Type and Molecular Target
        • Table Figure 41: Neurodegenerative Disease Drugs Market, Global, Clinical Program Size by Stage of Development, 2006–2018
        • Table Figure 42: Neurodegenerative Disease Drugs Market, Global, Clinical Program Size by Stage of Development and Indication, 2006–2018
        • Table Figure 43: Neurodegenerative Disease Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type, 2006–2018
        • Table Figure 44: Neurodegenerative Disease Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target, 2006–2017
    • Assessment of Key Pipeline Products
      • Aducanumab – Biogen/Eisai
        • Table Figure 45: Neurodegenerative Disease Drugs Market, Global, Revenue for Aducanumab ($bn), 2020–2023
      • Azeliragon – vTv Therapeutics
        • Table Figure 46: Neurodegenerative Disease Drugs Market, Global, Revenue for Azeliragon ($bn), 2019–2023
      • ChariSMA – AveXis
        • Table Figure 47: Neurodegenerative Disease Drugs Market, Global, Revenue for ChariSMA ($bn), 2019–2023
      • Omaveloxolone – Reata Pharmaceuticals
        • Table Figure 48: Neurodegenerative Disease Drugs Market, Global, Revenue for Omaveloxolone ($bn), 2019–2023
      • Siponimod – Novartis
        • Table Figure 49: Neurodegenerative Disease Drugs Market, Global, Revenue for Siponimod ($bn), 2019– 2023
      • Ozanimod – Celgene
        • Table Figure 50: Neurodegenerative Disease Drugs Market, Global, Revenue for Ozanimod ($bn), 2018–2023
      • Elenbecestat – Eisai
        • Table Figure 51: Neurodegenerative Disease Drugs Market, Global, Revenue for Elenbecestat ($m), 2020–2023
      • BAN-2401 – Sage Therapeutics
        • Table Figure 52: Neurodegenerative Disease Drugs Market, Global, Revenue for BAN-2401 ($m), 2020–2023
      • IONIS-HTTRx
        • Table Figure 53: Neurodegenerative Disease Drugs Market, Global, Revenue for IONIS-HTTRx ($m), 2020– 2023
    • Conclusion
  • Multi-scenario Market Forecast to 2023
    • Overall Market Size
      • Table Figure 54: Neurodegenerative Disease Drugs Market, Global, Market Size ($bn), 2016–2023
      • Table Figure 55: Neurodegenerative Disease Therapeutics Market, Global, Annual Revenue Forecast for Key Products ($m), 2016–2023
      • Table Figure 56: Neurodegenerative Disease Drugs Market, Global, Key Products Market Share, 2016–2023
    • Generic Penetration
      • Table Figure 57: Neurodegenerative Disease Drugs Market, Global, Annual Revenue by Premium and Generic Products ($bn), 2016–2023
      • Table Neurodegenerative Disease Drugs Market, Global, Usage of Generics Across Key Indications, 2018
    • Revenue Forecast by Molecular Target
      • Neuromodulators
        • Table Figure 58: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Neuromodulators ($bn), 2016–2023
      • Immunomodulators
        • Table Figure 59: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Immunomodulators ($bn), 2016–2023
      • Stress-related Targets
        • Table Figure 60: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Stressrelated inhibitors ($bn), 2016–2023
      • Protein Misfolding Targets
        • Table Figure 61: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Protein Misfolding and Aggregation Inhibitors ($bn), 2016–2023
      • Neuroprotectants
        • Table Figure 62: Neurodegenerative Disease Drugs Market, Global, Annual Revenue Forecast for Neuroprotectants ($bn), 2016–2023
  • Company Analysis and Positioning
    • Table Figure 63: Neurodegenerative Disease Drugs Market, Global, Company Analysis Matrix, 2016–2023
    • Table Figure 64: Neurodegenerative Disease Drugs Market, Global, Cluster Graph by Growth and Market Share, 2016–2023
    • Revenue and Market Share Analysis by Company
      • Table Figure 65: Neurodegenerative Disease Drugs Market, Global, Forecast Revenue by Company, 2016–2023
      • Table Figure 66: Neurodegenerative Disease Drugs Market, Global, Forecast Market Share by Company (%), 2016-2023
      • Table Figure 67: Neurodegenerative Disease Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2016-2023
      • Table Figure 68: Neurodegenerative Disease Drugs Market, Global, Revenue by Product Type, 2016-2023
      • Biogen – Aducanumab and Tecfidera Cement Biogen as the Market Leader
        • Table Figure 69: Neurodegenerative Disease Drugs Market, Global, Biogen Annual Revenue Forecast ($bn), 2016-2023
      • Roche – Increasing Sales of Ocrevus to Drive Market Size
        • Table Figure 70: Neurodegenerative Disease Drugs Market, Global, Roche Annual Revenue Forecast ($bn), 2016-2023
      • Novartis – Gradual Decline in Revenue due to Gilenya Patent Expiration Offset by Large Pipeline
        • Table Figure 71: Neurodegenerative Disease Drugs Market, Global, Novartis AG Annual Revenue Forecast ($bn), 2016-2023
      • Teva – Gradual Decline in Revenue due to Patent Expiration of Premium Product Copaxone
        • Table Figure 72: Neurodegenerative Disease Drugs Market, Global, Teva Annual Revenue Forecast ($bn), 2016-2023
      • Eisai – Elenbecestat and BAN-2401 Driving New Market Growth for Eisai
        • Table Figure 73: Neurodegenerative Disease Drugs Market, Global, Eisai Annual Revenue Forecast ($bn), 2016-2023
      • Sanofi – Aubagio and Lemtrada on Course for Blockbuster Status in 2023
        • Table Figure 74: Neurodegenerative Disease Drugs Market, Global, Sanofi Annual Revenue Forecast ($bn), 2016-2023
    • Company Landscape
      • Table Figure 75: Neurodegenerative Disease Drugs Market, Global, Companies by Type, 2018
    • Marketed and Pipeline Portfolio Analysis
      • Table Figure 76: Neurodegenerative Disease Drugs Market, Global, High-Activity and Late-Stage Developers by Level of Neurodegenerative Specialization, 2018
      • Table Figure 77: Neurodegenerative Disease Drugs Market, Global, Proportion of Total Company Revenue Attributed to Neurodegenerative Disorders, 2016–2023
      • Conclusion
  • Strategic Consolidations
    • Licensing Deals
      • Deals by Region, Year and Value
        • Table Figure 78: Neurodegenerative Disease Drugs Market, Global, Licensing Deals by Region, Year and Value, 2006-2018
      • Deals by Indication
        • Table Figure 79: Neurodegenerative Disease Drugs Market, Global, Licensing Deal Volume and Value by Indication, 2006–2018
      • Deals by Stage of Development and Value
        • Table Figure 80: Neurodegenerative Disease Drugs Market, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2018
      • Deals by Molecule Type and Molecular Target
        • Table Figure 81: Neurodegenerative Disease Drugs Market, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, 2006-2018
      • Table for Licensing Deals Valued Above $100m
        • Table Figure 82: Neurodegenerative Disease, Global, Licensing Deals with Disclosed Deal Values, 2006–2018
    • Co-development Deals
      • Deals by Region, Year and Value
        • Table Figure 83: Neurodegenerative Disease Drugs Market, Global, Co-development Deals by Region Value and Year, 2006–2018
      • Deals by Indication
        • Table Figure 84: Neurodegenerative Disease Drugs Market, Global, Co-development Deal Volume and Value by Indication, 2006–2018
      • Deals by Stage of Development and Value
        • Table Figure 85: Neurodegenerative Disease Drugs Market, Global, Co-development Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2018
      • Deals by Molecule Type, Mechanism of Action and Value
        • Table Figure 86: Neurodegenerative Disease Drugs Market, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006–2018
      • Table for Co-development Deals Valued Above $100m
        • Table Figure 87: Neurodegenerative Disease Drugs Market, Global, Co-development Deals with Disclosed Deal Values, 2006–2018
  • Appendix
    • Bibliography
    • All Pipeline Drugs by Phase
      • Discovery
        • Table Figure 88: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Discovery, 2018
      • Preclinical
        • Table Figure 89: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Preclinical, 2018
      • IND/CTA-Filed/Phase 0
        • Table Figure 90: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, IND/CTA-filed, 2018
      • Phase I
        • Table Figure 91: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Phase I, 2018
      • Phase II
        • Table Figure 92: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Phase II, 2018
      • Phase III
        • Table Figure 93: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Phase III, 2018
      • Pre-registration
        • Table Figure 94: Neurodegenerative Disease Drugs Market, Global, Pipeline Products, Pre-registration, 2018
    • Abbreviations
    • Disease List
      • Alzheimer's disease
      • Parkinson's disease
      • Multiple sclerosis
      • Amyotrophic lateral sclerosis
    • Methodology
      • Coverage
      • Secondary Research
      • Market Size and Revenue Forecasts
      • Pipeline Analysis
      • Competitive Landscape
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report